UnitedHealth Group Incorporated continues to navigate a turbulent health insurance landscape. With the potential passage of the “One Big Beautiful Bill Act” in Congress, President Donald Trump is poised to sign a measure that could sharply cut federal Medicaid funding. Current reports suggest that approximately 11.8 million Americans might lose their Medicaid benefits by 2034, with around 5.2 million impacted by new work requirements.
The bill aims to reduce state-level Medicaid expenses by gradually limiting “provider tax” revenue streams. At the same time, it allocates $50 billion to support rural hospitals facing these financial cuts. While UnitedHealth and Humana Inc. may initially feel pressure from a smaller Medicaid role, they could ultimately benefit as displaced members seek private insurance options.
UnitedHealth’s Medicaid enrollment has decreased by 4% in 2023, followed by a 5.2% decline in 2024 and 1.4% in the first quarter of 2025. Additionally, the possible elimination of the ACA market tax credit could push more individuals toward employer-sponsored plans. Meanwhile, cuts to Medicare savings programs could add to the burden, forcing older adults to manage higher out-of-pocket costs. On the brighter side, UnitedHealth’s Medicare Advantage enrollment rose by 8.3% in 2023, 1.9% in 2024, and 6.3% in the first quarter of 2025.
A significant shift in the market occurred when Centene Corporation, another major Medicaid player, withdrew its revenue guidance for 2025, citing unexpected changes in enrollment and rising healthcare costs. This move, echoing UnitedHealth’s earlier decisions, sent shockwaves through the managed care sector, resulting in substantial stock declines for Centene and its peers.
Following the announcement, Centene’s shares dropped by 41.2%, adversely affecting the stock prices of UnitedHealth and Humana, which fell by 5.4% and 5.1%, respectively.
From a valuation standpoint, UnitedHealth is currently trading at a favorable price ratio of 12.99, nicely above the industry average of 11.49, and holds an A score.
Zacks predicts that UnitedHealth’s revenues per share for 2025 will be $22.07, indicating a 20.2% decrease from the prior year’s figures. Currently, the stock carries a Zacks rank of #5, which suggests strong selling.
